ClinicalTrials.gg
Not yet recruitingNCT07752485Updated Aug 7, 2026

Effects of Long-Term Antihistamine Use on Mandibular Bone in Children

An observational study in Fractals and Panoramic Radiography, sponsored by Recep Tayyip Erdogan University Training and Research Hospital. Not yet recruiting. Open to participants aged 8 Years to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Recep Tayyip Erdogan University Training and Research Hospital · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
84
Ages
8 Years to 10 Years
Sex
All
01

Study summary

The purpose of this retrospective radiographic study is to evaluate the effects of long-term H1 antihistamine use on mandibular trabecular bone structure in children aged 8-10 years. Mandibular trabecular bone will be assessed using fractal dimension analysis and the panoramic mandibular index on digital panoramic radiographs. Three groups will be compared: children receiving long-term H1 antihistamine therapy, allergic children without antihistamine use, and age- and sex-matched healthy controls. The findings will provide information on whether long-term antihistamine therapy is associated with alterations in mandibular bone microarchitecture.

02

Conditions studied

  • Fractals
  • Panoramic Radiography
03

In context

Lead sponsor

Recep Tayyip Erdogan University Training and Research Hospital is the lead sponsor of 88 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of children aged 8 to 10 years who attended the Department of Oral and Maxillofacial Radiology at Recep Tayyip Erdoğan University Faculty of Dentistry and had diagnostic-quality digital panoramic radiographs obtained as part of routine dental care. Participants will include children receiving long-term H1 antihistamine therapy, allergic children without antihistamine therapy, and age- and sex-matched healthy controls.

Eligibility criteria

Inclusion Criteria

  • Children aged 8 to 10 years.
  • Availability of a diagnostic-quality digital panoramic radiograph obtained as part of routine dental care.
  • Presence of complete mandibular permanent first molars and permanent incisors.
  • Belonging to one of the following study groups:
  • Children receiving regular H1 antihistamine therapy for at least 12 months.
  • Children diagnosed with an allergic disease who have not received H1 antihistamine therapy during the previous 12 months.
  • Healthy children without allergic disease or long-term antihistamine use.
  • Availability of complete medical and dental records. Exclusion Criteria
  • History of systemic diseases or conditions known to affect bone metabolism.
  • Use of medications affecting bone metabolism (other than H1 antihistamines in the antihistamine group).
  • Craniofacial anomalies or syndromes.
  • History of orthodontic treatment.
  • Previous mandibular trauma or surgery.
  • Presence of radiographic pathology affecting the mandibular regions of interest (e.g., cysts, tumors, fractures, or extensive bone lesions).
  • Poor-quality panoramic radiographs with positioning errors or artifacts that interfere with image analysis.
  • Missing permanent first molars or incomplete eruption of teeth required for the analysis.
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
84 participants (estimated)
Patient registry
No

Groups and cohorts

  • Children Receiving Long-Term H1 Antihistamine Therapy

    Children aged 8-10 years who have been receiving H1 antihistamine therapy regularly for at least one year.

  • Allergic Children Without Antihistamine Therapy

    Children aged 8-10 years diagnosed with allergic disease who have not received H1 antihistamine therapy during the previous year.

  • Healthy Controls

    Age- and sex-matched healthy children without allergic disease or long-term antihistamine use.

06

What researchers measure

Primary outcomes

  1. Mandibular Trabecular Bone Structure Assessed by Fractal Dimension Analysis

    Mandibular trabecular bone structure will be evaluated on digital panoramic radiographs using fractal dimension analysis based on the box-counting method. Fractal dimension measurements will be performed bilaterally in three mandibular regions of interest: the subcortical region of the mandibular condyle, the supracortical region above the mandibular angle, and the dentate alveolar region distal to the mental foramen and superior to the mandibular canal. The right and left measurements for each region will be averaged to obtain one fractal dimension value per participant for each region. Fractal dimension values range from 1 to 2, with higher values indicating greater trabecular bone complexity. Values will be compared among children receiving long-term H1 antihistamine therapy, allergic children without antihistamine use, and healthy controls.

    Time frame: Baseline (retrospective panoramic radiographic assessment)

Secondary outcomes

  1. Panoramic Mandibular Index (PMI)

    The panoramic mandibular index (PMI) will be calculated on digital panoramic radiographs as the ratio of mandibular cortical width to the distance between the inferior border of the mandible and the inferior margin of the mental foramen. Measurements will be performed bilaterally, and the mean value of the right and left sides will be used for statistical analysis. Higher PMI values indicate relatively greater mandibular cortical thickness. Values will be compared among children receiving long-term H1 antihistamine therapy, allergic children without antihistamine use, and healthy controls.

    Time frame: Baseline (retrospective panoramic radiographic assessment)

  2. Klemetti Index (Mandibular Cortical Index, MCI)

    The Klemetti Index (Mandibular Cortical Index, MCI) will be assessed on digital panoramic radiographs by evaluating the endosteal margin of the mandibular cortex distal to the mental foramen. The mandibular cortex will be classified into three categories: C1 (normal cortex), C2 (moderately eroded cortex), and C3 (severely eroded and porous cortex). Higher categories indicate greater cortical erosion and reduced mandibular cortical integrity. The distribution of MCI categories will be compared among children receiving long-term H1 antihistamine therapy, allergic children without antihistamine use, and healthy controls.

    Time frame: Baseline (retrospective panoramic radiographic assessment)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Aug 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2026
First posted
Aug 7, 2026
StartEst.
Aug 3, 2026
Primary completionEst.
Aug 30, 2026
CompletionEst.
Sep 3, 2026
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07752485
Lead sponsor
Recep Tayyip Erdogan University Training and Research Hospital
Responsible party
DİLARA NİL GÜNAÇAR (Associate Professor, Recep Tayyip Erdogan University Training and Research Hospital) — Principal investigator
First posted
Aug 7, 2026
Start date
Aug 3, 2026 (estimated)
Primary completion
Aug 30, 2026 (estimated)
Completion
Sep 3, 2026 (estimated)
Last update
Aug 7, 2026

Study contacts

dilara nil günaçar
Contact
dilaranil.tomrukcu@erdogan.edu.tr
05412940104

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion